Phase I/II Trial of Abraxane [paclitaxel] in Combination with Carboplatin, Erbitux [cetuximab] and Intensity Modulated Radiation Therapy (IMRT) for Treatment of Locally Advanced Squamous Cancer of the Head and Neck

Trial Profile

Phase I/II Trial of Abraxane [paclitaxel] in Combination with Carboplatin, Erbitux [cetuximab] and Intensity Modulated Radiation Therapy (IMRT) for Treatment of Locally Advanced Squamous Cancer of the Head and Neck

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin; Cetuximab
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jun 2017 Status changed from completed to discontinued.
    • 18 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 09 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top